Partner 1
en
es
fr
pt
IRB Barcelona, Prof. Antonio Zorzano
Individual participants
- Dr. Antonio Zorzano, GT Leader: antonio.zorzano@irbbarcelona.org
- Dr.David Sebastián, Post Doc fellow: david.sebastian@irbbarcelona.org
- Mr.Ignacio Castrillón, Research assistant: ignacio.castrillon@irbbarcelona.org
- Ms.Laia Miret, PhD Student: laia.miret@irbbarcelona.org
- Dr. Jana Sánchez, Post Doc Fellow: jana.sanchez@irbbarcelona.org
- Ms. Caroline Mauvezin, PhD Student: caroline.mauvezin@irbbarcelona.org
- Ms. Ana Sancho, PhD Student: ana.sancho@irbbarcelona.org
- Dr. Manuela Sánchez-Feutrie, Research Associate: manuela.sanchez@irbbarcelona.org
- Mr. Carlos Barrabés, management: carlos.barrabes@irbbarcelona.org
- Mrs. Patricia Nadal, management: patricia.nadal@irbbarcelona.org
Research group: Molecular pathology and therapy in heterogenic and polygenic diseases.
We aim to determine the molecular mechanisms involved in the development of insulin resistance and, in particular, to identify novel obesity and type 2 diabetes susceptibility genes. This general objective is structured into three levels:
- Identification of genes responsible for the development of insulin resistance associated with obesity or type 2 diabetes with special emphasis on those genes implicated in novel mechanisms involving mitochondrial processes (i.e., mitochondrial dynamics), encoding proteins involved in the regulation of nuclear gene expression, or encoding proteins involved in novel signalling events.
- Analysis of the molecular mechanisms involved in the regulation of glucose transport in muscle and adipose cells and in the development of lipotoxicity.
- Identification of novel targets and development of new compounds for the treatment of the metabolic syndrome.
Our research group is organized around 3 research lines:
- Identification of genes responsible for the development of insulin resistance, obesity or type 2 diabetes
- Analysis of the molecular mechanisms involved in the regulation of glucose transport in muscle and adipose cells and in the development of lipotoxicity
- Identification of novel targets and development of new compounds for the treatment of the metabolic syndrome
Link to IRB Barcelona: www.irbbarcelona.org
Diomed Leaflet
